The impact on survival of CPT-11 as third-line or later treatment in advanced gastric cancer

被引：0

作者：

Makiyama, A. ^{[1
]}

Arimizu, K. ^{[1
]}

Hirano, G. ^{[1
]}

Makiyama, C. ^{[1
]}

Matsushita, Y. ^{[2
]}

Shirakawa, T. ^{[3
]}

Ohmura, H. ^{[4
]}

Komoda, M. ^{[4
]}

Uchino, K. ^{[4
]}

Inadomi, K. ^{[5
]}

Kusaba, H. ^{[6
]}

Shinohara, Y. ^{[7
]}

Kuwayama, M. ^{[7
]}

Kajitani, T. ^{[7
]}

Esaki, T. ^{[8
]}

Baba, E. ^{[9
]}

机构：

[1] Japan Community Healthcare Org Kyushu Hosp, Dept Hematol Oncol, Kitakyushu, Fukuoka, Japan

[2] Hamanomachi Hosp, Dept Med Oncol, Fukuoka, Japan

[3] Miyazaki Prefectural Miyazaki Hosp, Miyazaki, Japan

[4] Natl Hosp Org Kyushu Med Ctr, Dept Med Oncol, Fukuoka, Japan

[5] Kyushu Univ, Grad Sch Med Sci, Dept Med & Biosyst Sci, Fukuoka, Japan

[6] Kyushu Univ, Dept Med & Biosyst Sci, Fukuoka, Japan

[7] Kyushu Natl Canc Ctr, Fukuoka, Japan

[8] Kyushu Natl Canc Ctr, Dept Gastrointestinal & Med Oncol, Fukuoka, Japan

[9] Kyushu Univ, Dept Comprehens Clin Oncol, Fac Med Sci, Fukuoka, Japan

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P-171

引用

页码：51 / 51

页数：1

共 50 条

[31] Combination therapy with S-1 and irinotecan (CPT-11) for advanced or recurrent gastric cancer
Takiuchi, Hiroya
GASTRIC CANCER, 2009, 12 : 55 - 59
[32] Prognostic factor analysis of third-line chemotherapy in patients with advanced gastric cancer
Hyun Jeong Shim
Ju Young Yun
Jun Eul Hwang
Woo Kyun Bae
Sang Hee Cho
Ik Joo Chung
Gastric Cancer, 2011, 14 : 249 - 256
[33] Efficacy of the low dose apatinib plus deep hyperthermia as third-line or later treatment in HER-2 negative advanced gastric cancer
Han, Guohu
Sun, Changchun
Cui, Lihua
Huang, Yufeng
Yu, Lijiang
Liu, Shenzha
Tao, Min
PATHOLOGY & ONCOLOGY RESEARCH, 2023, 29
[34] Protocol of a phase II study investigating the efficacy and safety of trifluridine/tipiracil plus ramucirumab as a third-line or later treatment for advanced gastric cancer
Nakanishi, Koki
Tanaka, Chie
Kanda, Mitsuro
Miyata, Kazushi
Machida, Nozomu
Sakai, Mitsuru
Kobayashi, Daisuke
Teramoto, Hitoshi
Ishiyama, Akiharu
Sato, Bin
Oshima, Takashi
Kajikawa, Masaki
Matsushita, Hidenobu
Ishigure, Kiyoshi
Yamashita, Katsuya
Fujitake, Shinichi
Sueoka, Satoshi
Asada, Takahiro
Shimizu, Dai
Sugita, Shizuki
Kuwatsuka, Yachiyo
Maeda, Osamu
Furune, Satoshi
Murotani, Kenta
Ando, Yuichi
Ebata, Tomoki
Kodera, Yasuhiro
NAGOYA JOURNAL OF MEDICAL SCIENCE, 2024, 86 (01): : 43 - 51
[35] Combination therapy with S-1 and irinotecan (CPT-11) for advanced or recurrent gastric cancer
Hiroya Takiuchi
Gastric Cancer, 2009, 12 : 55 - 59
[36] Prognostic factor analysis of third-line chemotherapy in patients with advanced gastric cancer
Shim, Hyun Jeong
Yun, Ju Young
Hwang, Jun Eul
Bae, Woo Kyun
Cho, Sang Hee
Chung, Ik Joo
GASTRIC CANCER, 2011, 14 (03) : 249 - 256
[37] Prognostic factor for third-line chemotherapy in patients with advanced gastric cancer.
Choi, Jonggwon
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[38] CPT-11 as a second-line treatment for patients with advanced/metastatic gastric cancer who failed S-1 (CCOG0702)
Mochizuki, Yoshinari
Ohashi, Norifumi
Kojima, Hiroshi
Ishigure, Kiyoshi
Kinoshita, Takashi
Eguchi, Takehiko
Fujitake, Shinichi
Ito, Seiji
Fujiwara, Michitaka
Kodera, Yasuhiro
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (03) : 629 - 635
[39] Irinotecan (CPT-11) and cisplatin as first-line chemotherapy in advanced ovarian cancer.
Sugiyama, T
Noda, K
Yakushiji, M
Kamura, T
ANNALS OF ONCOLOGY, 2000, 11 : 86 - 86
[40] Factors, including clinical trial eligibility, associated with induction of third-line treatment for advanced gastric cancer
Ando, Takayuki
Hosokawa, Ayumu
Sakumura, Miho
Motoo, Iori
Kajiura, Shinya
Hirano, Katsuhisa
Miwa, Takeshi
Yokota, Tomotaka
Nakada, Naokatsu
Ueda, Yuko
Ueda, Akira
Tsukada, Kenichiro
Ogawa, Kohei
Nakaya, Atsuko
Teramoto, Akira
Nanjo, Sohachi
Mihara, Hiroshi
Fujinami, Haruka
Fujii, Tsutomu
Yasuda, Ichiro
ONCOLOGY, 2023, 101 (01) : 59 - 68

← 1 2 3 4 5 →